icon-    folder.gif   Conference Reports for NATAP  
  22nd Conference on Retroviruses and
Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
Back grey_arrow_rt.gif
Majority of HIV/HCV Co-Infected Patients Require Antiretroviral Therapy Switch Prior to Use of Simeprevir .....15% cant switch for resistance etc...31% on boosted PI cant switch
  Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
Rebecca Cope PharmD, Aaron Pickering PharmD, Thomas Glowa PharmD, Samantha Faulds BA, Peter Veldkamp MD, Ramakrishna Prasad MD, MPH Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA University of Pittsburgh School of Pharmacy, Pittsburgh, PA Baltimore Washington Medical Center, University of Maryland, Glen Burnie, MD
from Jules: this interesting study highlights that switching ART to accommodate drug interactions when beginning HCV therapy is more challenging than some expect, the authors said: "Majority of our HIV patients (76%) will need a change antiretroviral therapy in order to accommodate use of simeprevir for treatment of HCV - Efavirenz could invariably be switched to rilpivirine virologically - Majority of limitations were driven by protease inhibitor (PI) regimens - 31% on a boosted PI could not be switched to a safe and effective ART regimen - Most often due to use of salvage regimen where PI has become indispensable - Although fewer patients require switching ART to accommodate ledipasvir or paritaprevir/r, more than two-thirds will still need to be switched"